


4th SWISS AUTOIMMUNE LIVER DISEASE MEETING

 swissautoimmuneliver.com
fondazione.epatocentro@hin.ch

 21st - 22nd September 2023

 Aula Magna, USI Università della Svizzera Italiana West Campus
Via Giuseppe Buffi 13, 6900 Lugano, Switzerland

HOW TO GET THERE


From Lugano railway station, you can reach the Lugano Campus by bus or on foot. Take bus 6 (direction Cornaredo) from the square in front of the station. Alight at the "Università" stop (around 8-10 minutes' ride in normal traffic conditions).

By car: underground car park for the Lugano Campus available.



REMOTE PARTICIPATION

You can remotely attend through the QR code on the left.



REGISTRATION

You can register:

- on the website www.swissautoimmuneliver.com
- by sending an e-mail to fondazione.epatocentro@hin.ch
- through the QR code on the right



Patients' Session
Sponsor



Endorsements



www.epatocentro.ch/it/La-Fondazione

 /company/fondazione-epatocentro-ticino/

 /FondazioneEpatocentroTicino



Fondazione
Epatocentro Ticino

4th SWISS AUTOIMMUNE LIVER DISEASE MEETING

PATIENTS' SESSION

21st September 2023, 09:00 - 10:30



21st - 22nd
September 2023



Aula Magna USI Università
della Svizzera Italiana
Lugano, Switzerland



Remote
participation

Dear Patients,
Dear Families and Friends, and All Interested Parties,

It is our great pleasure to invite you to the session dedicated to you at the 4th Swiss Autoimmune Liver Disease Meeting. This is the fourth edition of the Meeting, which has seen your participation since the very beginning and now finally has a space dedicated to you. We have chosen three topics on which we often hear questions from you:

1. Is it possible to have children when suffering from autoimmune liver disease? What are the risks for the pregnancy? What is the risk for the unborn child to suffer from the same disease as the mother?
2. Drug therapy is extremely important, often life-saving. But what are the risks and side effects of drugs? What can be done to minimise and alleviate them?
3. What new therapies will be available in the future, especially for patients whose disease is not controlled by current therapies?

Some of the leading international experts will be present to talk about these issues, but also about anything else you may wish to ask. Translation will be available on site. **To facilitate the session we ask that you send your questions in advance by e-mail to: fondazione.epato-centro@hin.ch**

The session will include the participation of some patient associations (Swiss SwissHePa, UK PBC Foundation, Italian AMAF, German Deutsche Leberhilfe, and US Globalliver), which are extremely valuable to know for the numerous services they offer to patients, such as self-help groups and exchange of experiences and sharing, various information material on the diseases, tools to measure the impact of the disease on daily life (and thus give voice to the concrete needs of patients), and meetings with experts for information purposes, etc.

In addition to the session dedicated to patients there will be a space where Patients' Associations will be present for the whole duration of the meeting, providing the opportunity to meet and exchange experiences.

Participation in the scientific part of the meeting will be free of charge for all patients.

See you soon in Lugano!

Best wishes

The Scientific Committee
Benedetta Terziroli Beretta-Piccoli – Chair, Switzerland
Andreas Cerny, Switzerland
Andrea De Gottardi, Switzerland
Diego Vergani, UK
Giorgina Mieli-Vergani, UK
Andreas Kremer, Switzerland
Federica Sallusto, Switzerland

September 21st

from 08.30 **REGISTRATION**
Entrance hall

09:00–10:30 **PATIENTS' SESSION**
Pregnancy - *Michael Heneghan*
Drug side effects - *Maria Isabel Lucena and Raul Andrade*
New therapies - *Michael Manns*

With the participation of:
SwissHePa
UK PBC Foundation
AMAF
Deutsche Leberhilfe
Globalliver

11:00–11:15 **Welcome**
Benedetta Terziroli Beretta - Piccoli and Andrea De Gottardi
Welcome from Università della Svizzera Italiana - *Giovanni Pedrazzini*

BASIC SCIENCE SESSIONS

1 Genetics

Chairs: Gideon Hirschfield and Federica Sallusto

11:15 – 11:35 Genetics of PBC - *Pietro Invernizzi*
11:35 – 11:55 Genetics of PSC - *Tom Karlsen*
11:55 – 12:15 Genetics of AIH - *Ynto de Boer*
12:15 – 12:35 Inherited immune deficiencies and autoimmunity - *Mike Recher*
12:35 – 12:55 Discussion
12:55 – 13:45 **LUNCH**

2 Hot topics in autoimmune liver diseases

Chairs: Michael Manns and Michael Trauner

13:45 – 14:05 Cellular therapies
Maria Serena Longhi
14:05 – 14:25 SARS-CoV-2 and liver autoimmunity
Gideon Hirschfield
14:25 – 14:45 Pregnancy in autoimmune liver diseases patients
Michael Heneghan
14:45 – 15:05 Drug-induced AIH-like DILI
Maribel Lucena

15:05 – 15:25 Discussion

15:25 – 16:00 **COFFEE BREAK**

3 Oral presentations

Chairs: Michael Heneghan and
Giorgina Mieli-Vergani

16:00 – 16:15 Oral presentation 1
16:15 – 16:30 Oral presentation 2
16:30 – 16:45 Oral presentation 3
16:45 – 17:00 Oral presentation 4

4 Mechanisms of autoimmunity

Chairs: Diego Vergani and Andreas Cerny

17:00 – 17:20 The Long and Latent Road to Autoimmunity - *Eric Gershwin*
17:20 – 17:40 T cells in autoimmunity
Federica Sallusto
17:40 – 18:00 Viruses and autoimmunity
Christian Münz
18:00 – 18:20 Discussion

DAY 1

September 22st

CLINICAL SESSIONS

1 Diagnostic dilemmas

Chairs: Andrea De Gottardi and Andreas Kremer

08:30 – 08:45 Radiological clinical case presentation: the diagnosis of PSC
Stefano Cappio and his fellow
08:45 – 09:05 Imaging in PSC and ASC
Annamaria Deganello
09:05 – 09:20 Serological case presentation: the diagnosis of AIH - *Eric Dayer and Benedetta Terziroli Beretta-Piccoli*
09:20 – 09:40 Are autoantibodies still useful in the AI era? - *Diego Vergani*

09:40 – 10:00 Discussion

10:00 – 10:30 **COFFEE BREAK**

2 Treatment

Chairs: Kirsten Muri Boberg and Raul Andrade

10:30 – 10:50 Novel therapeutic targets for autoimmune cholestatic liver diseases - *Michael Trauner*
10:50 – 11:10 Treatment of cholestatic pruritus
Andreas Kremer

11:10 – 11:30 Difficult to treat AIH patients
Ansgar Lohse
11:30 – 11:50 Discussion

Oral presentations

Chairs: Benedetta Terziroli Beretta-Piccoli and
Pietro Invernizzi

11:50 – 12:05 Oral presentation 1
12:05 – 12:20 Oral presentation 2
12:20 – 12:35 Oral presentation 3
12:35 – 12:50 Oral presentation 4
12:50 – 13:50 **LUNCH**

3 Pediatrics

Chairs: Giorgina Mieli-Vergani and
Gideon Hirschfield

13:50 – 14:05 Case presentation
Christiane Sokollik
14:05 – 14:25 Sclerosing cholangitis in pediatric IBD patients
Patrick van Rheenen
14:25 – 14:45 Growing up with autoimmune liver disease: longterm outcome of autoimmune liver disease
Marianne Samyn

14:45 – 15:05 Discussion

15:05 – 15:30 **COFFEE BREAK**

4 Checkpoint-inhibitors and the liver

Chairs: Ansgar Lohse and Maria Isabel Lucena

15:30 – 15:45 Clinical case presentation
Antonio Galante
15:45 – 16:05 Checkpoint-inhibitors-induced liver injury
Eleonora de Martin
16:05 – 16:25 Liver histology of checkpoint-inhibitors-induced liver injury - *Yoh Zen*
16:25 – 16:45 Can checkpoint inhibitors be used in patients with autoimmune liver diseases?
Michael Manns
16:45 – 17:00 Discussion
17:00 – 17:20 Concluding remarks
Benedetta Terziroli Beretta-Piccoli
Andreas Kremer
Carina Bobzin
Robert Mitchell-Thain

MEETING ENDS

DAY 2